You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 24, 2024

VUITY Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Vuity patents expire, and when can generic versions of Vuity launch?

Vuity is a drug marketed by Abbvie and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has thirty-one patent family members in twenty-three countries.

The generic ingredient in VUITY is pilocarpine hydrochloride. There are twelve drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the pilocarpine hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Vuity

A generic version of VUITY was approved as pilocarpine hydrochloride by PADAGIS US on November 16th, 2004.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for VUITY?
  • What are the global sales for VUITY?
  • What is Average Wholesale Price for VUITY?
Summary for VUITY
Drug patent expirations by year for VUITY
Drug Prices for VUITY

See drug prices for VUITY

Pharmacology for VUITY
Paragraph IV (Patent) Challenges for VUITY
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
VUITY Ophthalmic Solution pilocarpine hydrochloride 1.25% 214028 1 2022-12-30

US Patents and Regulatory Information for VUITY

VUITY is protected by six US patents and two FDA Regulatory Exclusivities.

Patents protecting VUITY

Presbyopia treatments
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF PRESBYOPIA IN ADULTS BY ADMINISTRATION OF PILOCARPINE HCI FORMULATION TWICE DAILY

Presbyopia treatments
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF PRESBYOPIA IN ADULTS BY ADMINISTRATION OF PILOCARPINE HCI FORMULATION ONCE DAILY

Presbyopia treatments
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: USE OF VUITY FOR THE TREATMENT OF PRESBYOPIA IN ADULTS

Presbyopia treatments
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF PRESBYOPIA IN ADULTS BY ADMINISTRATION OF PILOCARPINE HCI FORMULATION ONCE DAILY

Presbyopia treatments
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF PRESBYOPIA IN ADULTS BY ADMINISTRATION OF PILOCARPINE HCI FORMULATION TWICE DAILY

Presbyopia treatments
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: USE OF VUITY FOR THE TREATMENT OF PRESBYOPIA IN ADULTS

FDA Regulatory Exclusivity protecting VUITY

ADDITION OF SECOND DOSE FOR TREATMENT OF PRESBYOPIA IN ADULTS
Exclusivity Expiration: ⤷  Sign Up

NEW PRODUCT
Exclusivity Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie VUITY pilocarpine hydrochloride SOLUTION;OPHTHALMIC 214028-001 Oct 28, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Abbvie VUITY pilocarpine hydrochloride SOLUTION;OPHTHALMIC 214028-001 Oct 28, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Abbvie VUITY pilocarpine hydrochloride SOLUTION;OPHTHALMIC 214028-001 Oct 28, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Abbvie VUITY pilocarpine hydrochloride SOLUTION;OPHTHALMIC 214028-001 Oct 28, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for VUITY

See the table below for patents covering VUITY around the world.

Country Patent Number Title Estimated Expiration
Croatia P20220762 ⤷  Sign Up
Slovenia 3681500 ⤷  Sign Up
Portugal 3681500 ⤷  Sign Up
Japan 6946575 ⤷  Sign Up
South Korea 20210005134 안구 증상의 치료를 위한 필로카르핀 염산염의 용도 ⤷  Sign Up
South Korea 20230079489 안구 증상의 치료를 위한 필로카르핀 염산염의 용도 (USE OF PILOCARPINE HYDROCHLORIDE FOR THE TREATMENT OF OCULAR CONDITIONS) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.